Advicenne Prepares its Expansion with Highly Experienced Industry Professionals
NÎMES, France--(BUSINESS WIRE)--Sep 25, 2018--Regulatory News:
Advicenne (Paris:ADVIC) (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today the appointment of Charlotte Sibley as Independent Director to its Board of Directors and Paul Michalet as Chief Financial Officer.
Ms. Sibley’s career in the healthcare industry spans 40 years. Her career includes contributing her expertise in market research at Pfizer, and in the medical device sector at Johnson & Johnson. Ms. Sibley also expanded her expertise to global pharma at Bristol-Myers Squibb and Pharmacia (now Pfizer), in biotech at Millennium Pharmaceuticals (now Takeda Oncology), and in consumer products at Lipton. She established the U.S. operations for a leading UK-based market research company, achieving profitability in 18 months in a highly competitive environment. Ms. Sibley also worked in New York at Donaldson, Lufkin & Jenrette as a security analyst for the pharmaceutical industry. She holds an MBA in Finance and Marketing from the University of Chicago Booth Graduate School of Business.
Ms. Sibley was named by the Healthcare Businesswomen’s Association 2008 Woman of the Year, in recognition of her leadership, business expertise and mentoring, and was among those named PharmaVoice’s Most Inspiring People in Pharma in 2006. Ms. Sibley serves on the Board of Directors of privately held Taconic Biosciences, Inc. and Fort Hill Company. Through 2014 she was a member of the Board of American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients and propulsion products. She is a National Association of Corporate Directors (NACD) Board Leadership Fellow and Governance Fellow.
“ Joining the Board of Directors of Advicenne is a great honor as the company has embarked on the goal of changing the daily lives of patients with unmet medical needs, ” stated Ms. Sibley. “ It is with great enthusiasm that I commence supporting Advicenne’s goals, which notably includes Advicenne’s expansion into the United States. ”
“ We are extremely pleased to welcome Charlotte to our Board of Directors, where her expertise will help our efforts to increase our footprint in the United States,” added Luc-André Granier, Chairman of the Board of Directors, Chief Executive Officer and co-founder of Advicenne. “I am also happy to announce the arrival of Paul Michalet as our Chief Financial Officer and look forward to his contribution as he will play a key role in accelerating the international growth of Advicenne.”
A graduate from Montpellier Business School, Mr. Michalet is a member of the SFAF (France Society of Financial Analysts) and of the IFA (French Institute of Board Directors). During the course of Mr. Michalet’s career, he has held various senior executive positions over the last 30 years. He served as Chief Financial Officer for 10 years in the manufacturing and service industries and, during the past 20 years, held senior executive positions in biotechnology companies in the chemical, cosmetics and pharmaceutical industries.
He most recently was Chief Executive Officer of a private biotech company specializing in monoclonal antibodies development for oncology and was previously Chief Financial Officer and Chief Business Officer for Fermentalg (Euronext: FALG).
In his previous senior positions, Mr. Michalet negotiated several important license agreements and raised more than €200m, including three successful IPOs: Fermentalg in 2014, Metabolic Explorer in 2007 and Coletica in 2000 (now BASF Beauty Care Solutions) for which he also prepared the trade sale.
“ Given its potential and maturity, joining Advicenne is truly a great opportunity. I look forward to helping the company and to become part of its ambitious future, ” said Mr. Michalet. “ The company has been extremely capital efficient and is now at a turning point. As we enter this exciting growth phase of Advicenne’s development, I am eager to share my experience as well as contribute to the team.”
Advicenne (Euronext: ADVIC) specializes in pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The French pharmaceutical company’s lead product, ADV7103, has achieved positive results in Europe in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). In addition to this indication, ADV7103 is being developed for Cystinuria, an inherited renal tubulopathy.
Advicenne plans to file ADV7103 for European market authorization for dRTA in the second half of 2018 and anticipates its commercial launch in 2020. In the United States, the FDA has cleared ADV7103’s Investigational New Drug (IND) application to initiate a pivotal phase III clinical trial assessing the drug in dRTA patients. Commercial launch in the United States is anticipated for 2021.
Advicenne is listed on the regulated market of Euronext in Paris (ISIN: FR0013296746; Euronext ticker: ADVIC). Established in 2007, the company is headquartered in Nîmes, France.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924006045/en/
Luc-André Granier, Sarah Delbaere, Julie Rachline, Paul Michalet
+33 (0)4 66 05 54 20
US Investor Relations
Rx Communications Group, LLC
Caroline Carmagnol & Tatiana Vieira
+33 (0)1 44 54 36 66
Emmanuel Huynh & Alexia Faure
+33 (0)1 44 71 94 94
KEYWORD: EUROPE FRANCE
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL FDA GENERAL HEALTH
Copyright Business Wire 2018.
PUB: 09/25/2018 01:45 AM/DISC: 09/25/2018 01:45 AM